Clinical trial
OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the…
NCT02988882 · Ocular Therapeutix, Inc., Industry · Completed
Key facts
| NCT number | NCT02988882 |
|---|---|
| Title | OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis |
| Official title | A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC®) |
| Lead sponsor | Ocular Therapeutix, Inc., Industry |
| Collaborators | ORA, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Allergic Conjunctivitis |
| Intervention type | Drug, Other |
| Interventions | Dexamethasone, Placebo Vehicle |
| Enrollment | 86 |
| Start date | Jun 1, 2015 |
| Primary completion | Apr 27, 2016 |
| Completion | Apr 27, 2016 |
| First posted | Dec 9, 2016 |
| Last update posted | Oct 12, 2020 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: